clonidine has been researched along with procainamide in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 12 (52.17) | 29.6817 |
| 2010's | 3 (13.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dresser, MJ; Giacomini, KM; Gray, AT; Terashita, S; Yost, SC; Zhang, L | 1 |
| Giacomini, KM; Schaner, ME; Zhang, L | 1 |
| Nezu, J; Oku, A; Sai, Y; Sakamoto, K; Shimane, M; Tamai, I; Tsuji, A; Yabuuchi, H | 1 |
| Chen, J; Conway, SJ; Ganapathy, V; Huang, W; Leibach, FH; Prasad, PD; Rajan, DP; Seth, P; Wu, X | 1 |
| Nezu, JI; Ohashi, R; Oku, A; Sai, Y; Shimane, M; Tamai, I; Tsuji, A; Yabuuchi, H | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Conway, SJ; Ganapathy, ME; Ganapathy, V; Huang, W; Kekuda, R; Leibach, FH; Wang, H; Wu, X | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Bednarczyk, D; Ekins, S; Wikel, JH; Wright, SH | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Almeyda, J; Levantine, A | 1 |
| Clark, BG; Vestal, RE | 1 |
| Shan, CW; Yang, JW; Yang, SQ | 1 |
2 review(s) available for clonidine and procainamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Cutaneous reactions to cardiovascular drugs.
Topics: Adrenergic beta-Antagonists; Cardiovascular Diseases; Clonidine; Debrisoquin; Digitalis Glycosides; Drug Eruptions; Ethacrynic Acid; Furosemide; Guanethidine; Humans; Hydralazine; Mercury; Methyldopa; Nitroglycerin; Pentaerythritol Tetranitrate; Procainamide; Quinidine; Thiazines | 1973 |
21 other study(ies) available for clonidine and procainamide
| Article | Year |
|---|---|
Cloning and functional expression of a human liver organic cation transporter.
Topics: Amino Acid Sequence; Animals; Base Sequence; Carrier Proteins; Cloning, Molecular; DNA, Complementary; Humans; Liver; Membrane Proteins; Molecular Sequence Data; Oocytes; Organic Cation Transporter 1; Polymerase Chain Reaction; Rats; RNA, Messenger; Sequence Homology, Amino Acid; Species Specificity; Tissue Distribution; Xenopus laevis | 1997 |
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
Topics: Carrier Proteins; Corticosterone; HeLa Cells; Humans; Membrane Proteins; Midazolam; Organic Cation Transporter 1; Permeability; Recombinant Proteins; Structure-Activity Relationship; Tetraethylammonium Compounds; Transfection | 1998 |
Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations.
Topics: Animals; Biological Transport, Active; Carrier Proteins; Cell Line; Gene Expression; Humans; Hydrogen-Ion Concentration; Membrane Potentials; Membrane Proteins; Membrane Transport Proteins; Oocytes; Organic Cation Transport Proteins; Quinidine; RNA, Messenger; Symporters; Tetraethylammonium Compounds; Xenopus laevis | 1999 |
Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.
Topics: Acetylcarnitine; Animals; Biological Transport, Active; Carnitine; Carrier Proteins; Humans; In Situ Hybridization; Kidney; Membrane Proteins; Mice; Myocardium; Organ Specificity; Organic Cation Transport Proteins; Placenta; Rats; RNA, Messenger; Solute Carrier Family 22 Member 5; Tetraethylammonium | 1999 |
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
Topics: Biological Transport, Active; Carnitine; Carrier Proteins; Cations; Cells, Cultured; Dose-Response Relationship, Drug; Embryo, Mammalian; Humans; Hydrogen-Ion Concentration; Kidney; Membrane Proteins; Organic Cation Transport Proteins; Sodium; Solute Carrier Family 22 Member 5; Stereoisomerism | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Amiloride; Animals; Binding, Competitive; Carbon Radioisotopes; Cations; Cloning, Molecular; DNA-Binding Proteins; DNA, Complementary; Dopamine Agents; Exons; Gene Expression Regulation; HeLa Cells; Herbicides; Humans; In Situ Hybridization; Introns; Kidney; Mice; Niacinamide; Octamer Transcription Factor-3; Oocytes; Pigment Epithelium of Eye; RNA, Messenger; Tetraethylammonium; Transcription Factors; Tritium; Xenopus laevis | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1.
Topics: Computational Biology; HeLa Cells; Humans; Models, Molecular; Organic Cation Transporter 1; Pyridinium Compounds; Quinolinium Compounds; Structure-Activity Relationship; Transfection | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Adverse drug reactions in the elderly: case studies.
Topics: Acetazolamide; Aged; Anemia, Hemolytic; Bromocriptine; Captopril; Chlorpropamide; Cimetidine; Clonidine; Dienestrol; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydralazine; Lung Diseases; Male; Middle Aged; Nitrofurantoin; Pancreatitis; Papaverine; Peripheral Nervous System Diseases; Procainamide; Propranolol; Sulindac; Theophylline; Timolol | 1984 |
Blockage of clonidine-induced platelet aggregation in rabbits by procainamide.
Topics: Animals; Binding, Competitive; Clonidine; Male; Platelet Aggregation Inhibitors; Procainamide; Rabbits; Receptors, Adrenergic, alpha | 1993 |